Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Microtest Labs Offers Fish Embryo Toxicity Testing | Contract Pharma

What are you searching for?

Sign in
Breaking News

Microtest Labs Offers Fish Embryo Toxicity Testing

FET test is OECD approved

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Microtest Laboratories is adding OECD Fish Embryo Toxicity Testing to its portfolio of services. The European Commission has recently added three pharmaceutical compounds to its pollutant watch list, citing them as potential environmental risks to surface water. The FET test is an approved OECD (Organization for Economic Co-Operative Development) guideline, published in August, 2013.
 
“Fish Embryo Toxicity (FET) testing has been developed for environmental and hazard classification applications. The test utilizes the embryo of the Zebrafish and exposes it to various compounds to observe potential toxic effects, thus making FET an ideal method to use in monitoring or investigating environmental cases,” said Steven Richter, Ph.D., president and scientific director of Microtest Laboratories — and former FDA official.
 
“Microtest Laboratories is deeply experienced in fish embryo toxicity testing. We are particularly well-suited to undertake FET testing due to the expertise we’ve developed in creating our Zebrafish Embryo Toxicity (ZET) test, which we’ve been providing as a preliminary screening method in the biocompatibility testing of medical devices and polymers.”
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics